| Literature DB >> 31720389 |
Unyeong Go1, Misun Park2, Un-Na Kim2, Sodam Lee2, Sunmi Han2, Joosun Lee2, Jiyeon Yang2, Jieun Kim2, Shinyoung Park2, Youngman Kim2, Hyosoon Yoo3, Jeongok Cha3, Wonseo Park3, Haeyoung Kang3, Hwon Kim3, Guri Park3, Minjung Kim3, Ok Park3, Hyunjin Son3, Enhi Cho3, Kyoungin Na3, Yunhyung Kwon2, Yeonkyeng Lee2, Kang Hee Lee2, Eunkyeong Jeong1, Dukhyoung Lee4, Byung-Guk Yang4, Byung-Yul Jeon4, Jong-Koo Lee4.
Abstract
Tuberculosis (TB) in Korea remains a serious health problem with an estimated 77 per 100,000 incidence rate for 2016. This makes Korea as the only OECD country with high incidence of TB. The government has increased budgets and strengthened patient management policies since 2011. The management of latent tuberculosis was added to the response with strengthened and extensive contact investigations in the five-year tuberculosis control plan (2013-2017) and implementation was established in 2013. Due to these efforts Korea has achieved an average 5.2% reduction annually in tuberculosis incidence rate between 2011 and 2016. To further expedite the reduction of the TB burden the government has introduced additional measures including mandatory screening of latent tuberculosis infection for community workers in congregate settings including daycare centers for children, kindergarten, and teachers in schools and health care workers in clinics and hospitals to solve the problems identified through contact investigations in 2017. Providing high quality free diagnosis and treatment of active TB including for multidrug resistant TB combined with active contact investigations is the mainstay of the current programmatic response in Korea. However, the limitation of existing tools for LTBI pose challenge including absence of best mechanism for effective communication with professionals and the public, the need for at least 3 months of treatment and the risk of side effects. Developing effective tools will help to overcome these challenges.Entities:
Keywords: Contact investigations; End TB; Epidemiology; Latent tuberculosis infection; Tuberculosis
Year: 2018 PMID: 31720389 PMCID: PMC6830170 DOI: 10.1016/j.jctube.2018.04.006
Source DB: PubMed Journal: J Clin Tuberc Other Mycobact Dis ISSN: 2405-5794
Fig. 1(New) TB notification rates, 2001–2016.
*Source: Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis in Korea. 2016.
Fig. 2(New) TB notification rates by gender and age, 2016.
*Source: Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis in Korea. 2016.
Treatment success rate among smear positive patients (%) (2011–2016).
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | |
|---|---|---|---|---|---|---|
| Treatment success rate among smear positive patients | 68.0 | 79.8 | 85.1 | 84.4 | 83.8 | 83.3 |
| Treatment success rate among MDR-TB patients | NA | NA | NA | 54.1 | 60.0 | 64.3 |
NA: Not available.
Fig. 3Flow chart for TB patient management and contact investigation.
Results of contact investigation among congregate settings by year (2013–2016).
| Year | 2013 | 2014 | 2015 | 2016 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of CI | No. of contacts | Contacts with TB disease | Contacts with LTBI (%) | No. of CI | No. of contacts | Contacts with TB disease | Contacts with LTBI (%) | No. of CI | No. of contacts | Contacts with TB disease | Contacts with LTBI (%) | No. of CI | No. of contacts | Contacts with TB disease | Contacts with LTBI (%) | |
| Total | 1142 | 145,486 | 262 | 14,049 | 1405 | 139,562 | 219 | 11,838 | 2639 | 130,838 | 272 | 13,252 | 3502 | 146,911 | 202 | 12,707 |
| (10.8) | (10.9) | (14.5) | (18.5) | |||||||||||||
| Schools | 750 | 123,011 | 192 | 9581 | 758 | 107,795 | 69 | 7652 | 708 | 74,761 | 96 | 4694 | 659 | 74,301 | 58 | 3182 |
| (8.6) | (8.6) | (7.8) | (8.8) | |||||||||||||
| Daycare- center/Kindergarten | 48 | 1961 | 0 | 392 | 37 | 1317 | 0 | 237 | 43 | 2167 | 0 | 228 | 46 | 3179 | 0 | 296 (15.1) |
| (21.0) | (20.1) | (13.5) | ||||||||||||||
| Elementary | 33 | 1628 | 1 | 215 | 44 | 4196 | 2 | 361 | 48 | 2325 | 2 | 278 | 64 | 4160 | 0 | 289 |
| (13.6) | (14.3) | (13.6) | (11.1) | |||||||||||||
| Middle | 89 | 12,624 | 4 | 886 | 85 | 10,329 | 8 | 910 | 62 | 9868 | 35 | 805 | 58 | 7617 | 6 | 608 |
| (7.7) | (9.2) | (9.3) | (9.5) | |||||||||||||
| High | 276 | 77,749 | 104 | 5913 | 245 | 58,043 | 29 | 4175 | 213 | 41,634 | 29 | 2448 | 183 | 43,988 | 38 | 1325 |
| (8.0) | (7.8) | (6.6) | (7.3) | |||||||||||||
| College | 293 | 28,246 | 81 | 2093 | 337 | 33,165 | 30 | 1824 | 329 | 18,390 | 30 | 902 | 295 | 14,799 | 14 | 619 |
| (9.8) | (8.5) | (8.5) | (9.1) | |||||||||||||
| Others | 11 | 803 | 2 | 82 | 10 | 745 | 0 | 145 | 13 | 377 | 0 | 33 | 13 | 558 | 0 | 45 |
| (10.7) | (20.7) | (12.6) | (15.3) | |||||||||||||
| Healthcare facilities | 81 | 3621 | 8 | 938 | 202 | 8827 | 73 | 1370 | 549 | 21,014 | 103 | 3070 | 856 | 29,219 | 83 | 3203 |
| (39.8) | (33.8) | (34.8) | (32.8) | |||||||||||||
| Military/Police unit | 108 | 9029 | 28 | 1045 | 135 | 10,307 | 32 | 1000 | 112 | 6176 | 6 | 565 | 128 | 5379 | 8 | 426 |
| (12.7) | (11.6) | (11.4) | (12.5) | |||||||||||||
| Social welfare/Correctional facilities | 147 | 7971 | 23 | 2072 | 189 | 8906 | 32 | 1225 | 357 | 11,618 | 31 | 1623 | 574 | 15,820 | 30 | 2013 |
| (34.8) | (34.1) | (35.1) | (37.8) | |||||||||||||
| Workplaces | 31 | 1326 | 11 | 329 | 91 | 2889 | 13 | 497 | 845 | 14,942 | 31 | 3034 | 1167 | 19,429 | 22 | 3598 |
| (27.8) | (26.4) | (28.0) | (30.8) | |||||||||||||
| Others | 25 | 528 | 0 | 84 | 30 | 838 | 0 | 94 | 68 | 2327 | 5 | 266 | 118 | 2763 | 1 | 285 |
| (17.2) | (12.1) | (14.2) | (13.0) | |||||||||||||
LTBI treatment completion rate by treatment regimen (2013–2014).
| Regimens | Number of treatment initiations among LTBI cases | Number of completed LTBI treatments | Treatment completion rate (%) |
|---|---|---|---|
| Total | 10,822 | 8985 | 83.0 |
| Isoniazid and rifampicin 3 months | 3157 | 2791 | 88.4 |
| Rifampicin 4 months | 930 | 820 | 88.2 |
| Isoniazid 9 months | 6735 | 5374 | 79.8 |
New TB notification cases and rates by type of TB, 2011–2016.
| Year | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | % of reduction of new TB notification rate, 2011–2016 | % of annual decrease rate of new TB notification rate, 2011–2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Rate | Case | Rate | Case | Rate | Caser | Rate | Case | Rate | Case | Rate | ||||
| New TB notification | 39,557 | 78.9 | 39,545 | 78.5 | 36,089 | 71.4 | 34,869 | 68.7 | 32,181 | 63.2 | 30,892 | 60.4 | −23.4 | −5.2 | |
| Pulmonary TB | Sub-Total | 30,100 | 60.1 | 31,075 | 61.7 | 28,720 | 56.8 | 27,906 | 55.0 | 25,550 | 50.1 | 24,696 | 48.3 | −19.6 | −4.3 |
| Smear-positive pulmonary TB | 11,714 | 23.4 | 12,137 | 24.1 | 11,100 | 22.0 | 10,446 | 20.6 | 9309 | 18.3 | 8812 | 17.2 | −26.2 | −5.9 | |
| Extrapulmonary TB | 9457 | 18.9 | 8470 | 16.8 | 7369 | 14.6 | 6963 | 13.7 | 6631 | 13.0 | 6196 | 12.1 | −35.8 | −8.5 | |
Rate are per 100,000 population.
Fig. 4New TB notification rates by age group from 2011 to 2016.
New TB notification cases and rates by age, 2011–2016.
| Year | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | % of reduction of new TB notification rate, 2011–2016 | % of annual decrease rate of new TB notification rate, 2011–2016 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Rate | Case | Rate | Case | Rate | Case | Rate | Case | Rate | Case | Rate | |||
| Total | 39,557 | 78.9 | 39,545 | 78.5 | 36,089 | 71.4 | 34,869 | 68.7 | 32,181 | 63.2 | 30,892 | 60.4 | −23.4 | −5.2 |
| 0–4 | 59 | 2.6 | 59 | 2.5 | 40 | 1.7 | 40 | 1.7 | 23 | 1.0 | 17 | 0.8 | −69.2 | −21.0 |
| 5–9 | 38 | 1.6 | 42 | 1.8 | 25 | 1.1 | 21 | 0.9 | 16 | 0.7 | 13 | 0.6 | −62.5 | −17.8 |
| 10–14 | 305 | 9.6 | 199 | 6.5 | 155 | 5.4 | 115 | 4.2 | 128 | 5.0 | 102 | 4.2 | −56.3 | −15.2 |
| 15–19 | 2030 | 57.3 | 1630 | 46.5 | 1281 | 37.2 | 1131 | 33.6 | 1014 | 30.9 | 750 | 23.5 | −59.0 | −16.3 |
| 20–24 | 2496 | 79.0 | 2365 | 72.7 | 2099 | 62.7 | 1988 | 57.9 | 1671 | 47.6 | 1419 | 40.1 | −49.2 | −12.7 |
| 25–29 | 3127 | 86.9 | 2895 | 85.4 | 2465 | 76.4 | 2218 | 70.4 | 1928 | 61.6 | 1760 | 55.7 | −35.9 | −8.5 |
| 30–34 | 2852 | 72.2 | 2659 | 66.3 | 2442 | 60.4 | 2092 | 52.7 | 1794 | 47.3 | 1548 | 43.0 | −40.4 | −9.8 |
| 35–39 | 2620 | 61.3 | 2422 | 58.7 | 2070 | 52.1 | 1935 | 49.9 | 1689 | 43.5 | 1533 | 38.9 | −36.5 | −8.7 |
| 40–44 | 2812 | 62.6 | 2785 | 61.0 | 2608 | 57.2 | 2450 | 54.3 | 2078 | 47.1 | 1863 | 43.8 | −30.0 | −6.9 |
| 45–49 | 2915 | 69.1 | 2907 | 70.1 | 2650 | 63.2 | 2546 | 59.2 | 2211 | 50.6 | 2165 | 48.5 | −29.8 | −6.8 |
| 50–54 | 3,320 | 80.2 | 3,324 | 77.5 | 3,107 | 71.6 | 2,978 | 68.9 | 2,699 | 63.3 | 2,448 | 58.7 | −26.8 | −6.1 |
| 55–59 | 2761 | 91.0 | 2976 | 91.6 | 2758 | 79.9 | 2916 | 79.3 | 2785 | 71.7 | 2719 | 66.7 | −26.7 | −6.0 |
| 60–64 | 2363 | 104.3 | 2452 | 104.8 | 2227 | 91.9 | 2228 | 88.4 | 2207 | 81.3 | 2227 | 75.1 | −28.0 | −6.4 |
| 65+ | 11,859 | 214.6 | 12,798 | 222.2 | 12,157 | 201.6 | 12,211 | 193.9 | 11,938 | 182.2 | 12,328 | 181.8 | −15.3 | −3.3 |
32 cases with age unknown.
5 cases with age unknown.
Rate are per 100,000 population.